Novo Nordisk A/S (NVO)

NYSE · Healthcare · Drug Manufacturers - General
$37.82-2.70%As of 2026-11-22 · USD
Last session low $37.75Last session high $39.11
52-week low $35.1252-week high $64.16
Market cap
$166.69B
Sector
Healthcare
P/E (TTM)
9.6x
Dividend yield
4.75%
Next earnings
2027-02-03

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)40.0In the neutral range (30 to 70)
MACD (12, 26, 9)-0.05Below its signal line (0.17); histogram -0.22
Bollinger %B (20, 2)-2%Below the lower band (37.91 to 42.39)
SMA 2040.15Price is 5.8% below
SMA 5039.60Price is 4.5% below
SMA 20042.27Price is 10.5% below
ATR (20)2.86% of priceAverage true range per day
52-week position9%In the lower part of the 35.12 to 64.16 range

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Latest fiscal yearEnded 2025-12-31: revenue of 309.06B DKK and an operating margin of 41.3%.
Next earnings reportExpected on 2027-02-03.

Also listed as NOV.DE (XETRA), NOVO-B.CO (Copenhagen)

More in Drug Manufacturers - General